About Corcept Therapeutics Incorporated
https://www.corcept.comCorcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.
CEO
Joseph K. Belanoff
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 185
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:16.54M
Value:$612.61M
BLACKROCK, INC.
Shares:12.05M
Value:$446.25M
VANGUARD GROUP INC
Shares:9.54M
Value:$353.25M
Summary
Showing Top 3 of 507
About Corcept Therapeutics Incorporated
https://www.corcept.comCorcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $207.64M ▲ | $192.82M ▲ | $19.36M ▼ | 9.32% ▼ | $0.19 ▼ | $15.72M ▼ |
| Q2-2025 | $194.43M ▲ | $164.32M ▲ | $35.15M ▲ | 18.08% ▲ | $0.33 ▲ | $27.14M ▲ |
| Q1-2025 | $157.21M ▼ | $151.4M ▼ | $20.29M ▼ | 12.9% ▼ | $0.19 ▼ | $3.88M ▼ |
| Q4-2024 | $181.89M ▼ | $153.67M ▲ | $30.39M ▼ | 16.71% ▼ | $0.29 ▼ | $25.72M ▼ |
| Q3-2024 | $182.55M | $133.08M | $46.69M | 25.58% | $0.45 | $47.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $421.68M ▲ | $823.61M ▲ | $191.71M ▲ | $631.9M ▼ |
| Q2-2025 | $342.23M ▲ | $801.72M ▼ | $165.93M ▲ | $635.79M ▼ |
| Q1-2025 | $322.76M ▼ | $846.46M ▲ | $163.17M ▲ | $683.28M ▲ |
| Q4-2024 | $383.33M ▲ | $840.55M ▲ | $160.96M ▲ | $679.59M ▲ |
| Q3-2024 | $380.34M | $784.26M | $145.42M | $638.84M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $19.36M ▼ | $54.48M ▲ | $14.64M ▼ | $-46.41M ▲ | $22.39M ▲ | $54.48M ▲ |
| Q2-2025 | $35.15M ▲ | $43.94M ▲ | $70.13M ▲ | $-102.93M ▼ | $12.93M ▲ | $43.88M ▲ |
| Q1-2025 | $20.55M ▼ | $5.13M ▼ | $-3.17M ▲ | $-39.8M ▼ | $-37.85M ▼ | $5.02M ▼ |
| Q4-2024 | $30.39M ▼ | $59.3M ▼ | $-64.36M ▼ | $-4.56M ▲ | $-9.62M ▼ | $59.18M ▼ |
| Q3-2024 | $46.69M | $73.83M | $-44.04M | $-21.09M | $8.7M | $72.19M |
CEO
Joseph K. Belanoff
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 185
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:16.54M
Value:$612.61M
BLACKROCK, INC.
Shares:12.05M
Value:$446.25M
VANGUARD GROUP INC
Shares:9.54M
Value:$353.25M
Summary
Showing Top 3 of 507